XANTHUS PHARMACEUTICALS, INC. LICENSES NOVEL CANCER TARGETING AGENTS FROM SCHERING AG

Xanthus Pharmaceuticals, Inc., a privately held oncology drug development company, announced that the company has acquired from Schering AG, Berlin, the exclusive worldwide rights to develop and commercialize a group of targeted cancer compounds. The lead compound is P2045, which Xanthus intends initially to develop for the treatment of advanced lung cancer. BioSpace (http://www.biospace.com/news_story.aspx?StoryID=29080&full=1)